A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia (original) (raw)

References

  1. Sellick, G.S., Catovsky, D. & Houlston, R.S. Familial chronic lymphocytic leukemia. Semin. Oncol. 33, 195–201 (2006).
    Article PubMed Google Scholar
  2. Raval, A. et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879–890 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  3. Sellick, G.S. et al. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood 110, 3326–3333 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  4. Power, C. & Elliott, J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34–41 (2006).
    Article PubMed Google Scholar
  5. Pfeifer, D. et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109, 1202–1210 (2007).
    Article CAS PubMed Google Scholar
  6. Busslinger, M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 22, 55–79 (2004).
    Article CAS PubMed Google Scholar
  7. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8, 22–33 (2008).
    Article CAS PubMed Google Scholar
  8. Shapiro-Shelef, M. & Calame, K. Regulation of plasma-cell development. Nat. Rev. Immunol. 5, 230–242 (2005).
    Article CAS PubMed Google Scholar
  9. Bloch, D.B., de la Monte, S.M., Guigaouri, P., Filippov, A. & Bloch, K.D. Identification and characterization of a leukocyte-specific component of the nuclear body. J. Biol. Chem. 271, 29198–29204 (1996).
    Article CAS PubMed Google Scholar
  10. Dent, A.L. et al. LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. Blood 88, 1423–1426 (1996).
    CAS PubMed Google Scholar
  11. Ling, P.D. et al. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24, 3565–3575 (2005).
    Article CAS PubMed PubMed Central Google Scholar
  12. Madani, N. et al. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J. Virol. 76, 11133–11138 (2002).
    Article CAS PubMed PubMed Central Google Scholar
  13. Oliver, P.M. et al. Loss of Bim allows precursor B cell survival but not precursor B cell differentiation in the absence of interleukin 7. J. Exp. Med. 200, 1179–1187 (2004).
    Article CAS PubMed PubMed Central Google Scholar
  14. Kovalevska, L.M. et al. Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp. Oncol. 28, 225–230 (2006).
    CAS PubMed Google Scholar
  15. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999).
    CAS PubMed Google Scholar
  16. Damle, R.N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840–1847 (1999).
    CAS PubMed Google Scholar
  17. Weiss, N.S. Geographical variation in the incidence of the leukemias and lymphomas. Natl. Cancer Inst. Monogr. 53, 139–142 (1979).
    Google Scholar
  18. Catovsky, D. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370, 230–239 (2007).
    Article CAS PubMed Google Scholar
  19. Sayala, H. et al. Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group). Blood (ASH Annual Meeting Abstracts) 108, 34 (2006).
    Google Scholar
  20. Allan, J.M. et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. USA 98, 11592–11597 (2001).
    Article CAS PubMed PubMed Central Google Scholar
  21. van Krieken, J.H. et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4–CT98–3936. Leukemia 21, 201–206 (2007).
    Article CAS PubMed Google Scholar
  22. Petitti, D. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis (Oxford Univ. Press, New York, 1994).
  23. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
    Article PubMed Google Scholar
  24. Cox, A. et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39, 352–358 (2007).
    Article CAS PubMed Google Scholar
  25. Goldin, L.R., Pfeiffer, R.M., Li, X. & Hemminki, K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 104, 1850–1854 (2004).
    Article CAS PubMed Google Scholar
  26. Stranger, B.E. et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
    Article PubMed PubMed Central Google Scholar
  27. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848–853 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  28. Cuzick, J.A. Wilcoxon-type test for trend. Stat. Med. 4, 87–90 (1985).
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

Leukaemia Research Fund (LRF) provided principal funding for the study (LRF05001 and 06002). Additional funding was provided by CLL Global Research Foundation, Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund), the Arbib fund and the European Union (CPRB LSHC-CT-2004-503465). D.C.-S. was in receipt of a PhD studentship from the Institute of Cancer Research. We are grateful to M. Yuille for input into our early work on familial CLL. This study made use of genotyping data on the 1958 Birth Cohort. Genotyping data on controls was generated and generously supplied to us by P. Deloukas of the Wellcome Trust Sanger Institute. A full list of the investigators who contributed to the generation of the data are available from http://www.wtccc.org.uk. We are grateful to all investigators who contributed to the study of acute leukemia, from which phase 3 controls were drawn, to members of the ICLLLC (Supplementary Note online) and to investigators who contributed to NSCCG and GELCAPS, from which phase 1 and 2 controls were drawn. Finally, we are grateful to all the study subjects for their participation.

Author information

Author notes

  1. Maria Chiara Di Bernardo, Dalemari Crowther-Swanepoel and Peter Broderick: These authors contributed equally to this work.

Authors and Affiliations

  1. Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, Surrey, UK
    Maria Chiara Di Bernardo, Dalemari Crowther-Swanepoel, Peter Broderick, Emily Webb, Gabrielle Sellick, Ruth Wild, Kate Sullivan, Jayaram Vijayakrishnan, Yufei Wang, Alan M Pittman & Richard S Houlston
  2. Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
    Nicola J Sunter, Andrew G Hall & James M Allan
  3. MRC Toxicology Unit, Leicester University, Leicester, LE1 9HN, UK
    Martin J S Dyer
  4. Section of Haemato-oncology, Institute of Cancer Research, Sutton, SM2 5NG, Surrey, UK
    Estella Matutes, Claire Dearden & Daniel Catovsky
  5. Haematological Sciences, Leech Building, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
    Tryfonia Mainou-Fowler
  6. Department of Haematology, Royal Victoria Infirmary, Newcastle-upon-Tyne, NE1 4LP, UK
    Graham H Jackson
  7. Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle-upon-Tyne, NE9 6SX, UK
    Geoffrey Summerfield
  8. Division of Haematology, University of Liverpool School of Cancer Studies, Liverpool, UK
    Robert J Harris & Andrew R Pettitt
  9. Department of Haematology, Leeds General Infirmary, Leeds, LS1 3EX, UK
    Peter Hillmen
  10. Department of Haematology, Hull Royal Infirmary, Hull, HU3 2JZ, UK
    David J Allsup
  11. Hull York Medical School and University of Hull, Hull, HU16 5JQ, UK
    James R Bailey
  12. Department of Haematology, Birmingham Heartlands Hospital, Birmingham, B9, UK
    Guy Pratt
  13. Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Chris Pepper
  14. Cardiff and Vale NHS Trust, Heath Park, Cardiff, CF14 4XW, UK
    Chris Fegan

Authors

  1. Maria Chiara Di Bernardo
  2. Dalemari Crowther-Swanepoel
  3. Peter Broderick
  4. Emily Webb
  5. Gabrielle Sellick
  6. Ruth Wild
  7. Kate Sullivan
  8. Jayaram Vijayakrishnan
  9. Yufei Wang
  10. Alan M Pittman
  11. Nicola J Sunter
  12. Andrew G Hall
  13. Martin J S Dyer
  14. Estella Matutes
  15. Claire Dearden
  16. Tryfonia Mainou-Fowler
  17. Graham H Jackson
  18. Geoffrey Summerfield
  19. Robert J Harris
  20. Andrew R Pettitt
  21. Peter Hillmen
  22. David J Allsup
  23. James R Bailey
  24. Guy Pratt
  25. Chris Pepper
  26. Chris Fegan
  27. James M Allan
  28. Daniel Catovsky
  29. Richard S Houlston

Contributions

R.S.H. designed the study with the assistance of G.S.; R.S.H. drafted the manuscript, with substantial contributions from E.W., M.C.D.B. and D.C.-S. M.C.D.B. performed statistical analyses with contributions from E.W. and Y.W. D.C.-S., M.C.D.B. and A.M.P. performed bioinformatics analyses. Phases 1 and 2: P.B. performed laboratory management and oversaw genotyping of cases and controls; D.C.-S., K.S. and J.V. conducted sequencing; D.C.-S. conducted genotyping of cases and controls; R.S.H., G.S., D.C., E.M., C.D. and D.C.-S. developed protocols for recruitment of individuals with CLL and sample acquisition and performed sample collection of cases; members of the ICLLLC consortium carried out ascertainment of familial cases (Supplementary Note). Phase 3: J.M.A. and D.J.A. conceived of the Newcastle-based CLL study. J.M.A. established the study, supervised laboratory management and oversaw genotyping of cases and controls. N.J.S. performed sample management of cases and controls. A.G.H. developed the Newcastle Haematology Biobank, incorporating the Newcastle-based CLL study. T.M.-F., G.H.J., G.S., R.J.H., A.R.P., P.H., D.J.A., J.R.B., G.P., C.P. and C.F. developed protocols for recruitment of individuals with CLL and sample acquisition and performed sample collection of cases. All authors contributed to the final paper.

Corresponding author

Correspondence toRichard S Houlston.

Supplementary information

Rights and permissions

About this article

Cite this article

Di Bernardo, M., Crowther-Swanepoel, D., Broderick, P. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.Nat Genet 40, 1204–1210 (2008). https://doi.org/10.1038/ng.219

Download citation